Table 2 IC 50 for primary AML patient... | American Society of Hematology

Table 2

IC₅₀ for primary AML patient samples

Patient no.	Age, y	WHO classification	WBCs*	Cytogenetics	NPM1	FLT3	IC₅₀, nM
1	27	Acute myelomonocytic leukemia	39	46,XX(20)	Mut (A)	WT	100
2	42	AML with maturation	26	46,XY(20)	Mut (A)	WT	100
3	62	AML without maturation	199	46,XX(20)	Mut (A)	WT	100
4	77	AML with maturation	85	46,XY(20)	Mut (A)	WT	50
5	62	AML with MDS-related changes	8.8	46,XY(20)	WT	WT	500
6	52	AML with maturation	75	46,XY(20)	WT	WT	500
7	45	Acute myelomonocytic leukemia	53	46,XX(20)	WT	WT	500
8	56	Acute myelomonocytic leukemia	69	46,XX(20)	WT	ITD+	500
9	20	AML with inv(16)	45	46,XX,inv(16)	WT	WT	500
10	53	Acute myelomonocytic leukemia	79	46,XX(20)	WT	ITD+	500
11	85	AML without maturation	66	46,XY(20)	WT	ITD+	500
12	52	AML with t(8;21)	2.9	45,X,−X,t(8;21)	WT	WT	500
13	50	AML with t(8;21)	15.6	45,X,−Y,t(8;21)	WT	WT	500

Patient no.	Age, y	WHO classification	WBCs*	Cytogenetics	NPM1	FLT3	IC₅₀, nM
1	27	Acute myelomonocytic leukemia	39	46,XX(20)	Mut (A)	WT	100
2	42	AML with maturation	26	46,XY(20)	Mut (A)	WT	100
3	62	AML without maturation	199	46,XX(20)	Mut (A)	WT	100
4	77	AML with maturation	85	46,XY(20)	Mut (A)	WT	50
5	62	AML with MDS-related changes	8.8	46,XY(20)	WT	WT	500
6	52	AML with maturation	75	46,XY(20)	WT	WT	500
7	45	Acute myelomonocytic leukemia	53	46,XX(20)	WT	WT	500
8	56	Acute myelomonocytic leukemia	69	46,XX(20)	WT	ITD+	500
9	20	AML with inv(16)	45	46,XX,inv(16)	WT	WT	500
10	53	Acute myelomonocytic leukemia	79	46,XX(20)	WT	ITD+	500
11	85	AML without maturation	66	46,XY(20)	WT	ITD+	500
12	52	AML with t(8;21)	2.9	45,X,−X,t(8;21)	WT	WT	500
13	50	AML with t(8;21)	15.6	45,X,−Y,t(8;21)	WT	WT	500

Mut indicates mutated; and WT, wild-type.

× 10⁵.